Why Intervacc stock moves
Intervacc fell, more than the market, which was clearly lower.
Written after the close on ·
Earnings report
Next report: November 12. On its last 15 report days Intervacc usually moved about 7.4%. On a normal day it moves 2.0%.
August 20, 2026: −1.08%May 13, 2026: −14.82%February 17, 2026: −16.47%November 19, 2025: −1.06%
Why today
16,416 news analyzed todayIntervacc fell, more than the market, which was clearly lower.
No company news from that session explains the move.
Over the last five trading days the shares were roughly unchanged, while the market was also roughly flat.
Trading was about twice a normal day, and the share sits well below its high from mid May.
Earlier Strangvac vaccine data on real-world protection came out on Tuesday, and the next earnings report is on Thursday 12 November.
Today's move of −5.24% was 2.6 times a normal day's 2.0%. OMX Stockholm 30 moved −1.01% on the same day.
Intervacc −5.24%OMX Stockholm 30 −1.01%Much weaker than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Intervacc.
Intervacc earned more than expected in 3 out of 5 reports.
Not in the chart because no estimate and result are available: 2 of the 7 reports in this period, the latest on August 20, 2026.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 3 out of 5 reports with a measured move, against about 63% of reports from Nordic companies.
Price targets
Latest price 0.78 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of -0.06 SEK (November 12). For the current fiscal year, expected earnings per share changed from -0.22 SEK three months ago to -0.23 SEK now. 2026 estimate: -0.23 SEK. 2027 estimate: -0.24 SEK. One analyst made these estimates. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. August 31: Buy about 7 thousand SEK. August 26: Buy about 21 thousand SEK. August 25: Buy about 10 thousand SEK. August 21: Buy about 4 thousand SEK. July 17: Buy about 12 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −21% and earnings per share went from -0.86 SEK to -0.27 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 265 m SEKRevenue 2025: 20.1 m SEK
What the key figures say about Intervacc
The figures connect what Intervacc earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -1.36 SEK–-0.27 SEK. Peers: Oncoinvent -83.20 NOK, Cantargia 0.68 SEK, Diamyd Medical -1.80 SEK. 2026 estimate: -0.23 SEK (-0.23 SEK–-0.23 SEK). 2027 estimate: -0.24 SEK (-0.24 SEK–-0.24 SEK).
What the company sold during the year.
2022–2025: 8.0 m SEK–20.1 m SEK. Peers: Oncoinvent 24.3 m NOK, Cantargia 317 m SEK, Diamyd Medical 0.5 m SEK. 2026 estimate: 21.0 m SEK (20.0 m SEK–22.0 m SEK). 2027 estimate: 30.0 m SEK (30.0 m SEK–30.0 m SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: −1167.5%–−415.7%. Peers: Oncoinvent −593.4%, Cantargia 52.3%, Diamyd Medical −53999.8%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −46.5%–−25.6%. Peers: Oncoinvent −228.1%, Cantargia 113.5%, Diamyd Medical −97.6%.
What investors pay for each unit the company sells.
2022–2025: 8.76–158.01. Peers: Oncoinvent 15.78, Cantargia 1.26, Diamyd Medical 317.44. 2026 estimate: 12.63. 2027 estimate: 8.84.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 0.64–6.12. Peers: Oncoinvent 3.48, Cantargia 1.51, Diamyd Medical 0.62.
Cash left after investments, divided by the number of shares.
2022–2025: -1.12 SEK–-0.20 SEK. Peers: Oncoinvent -21.21 NOK, Cantargia 0.58 SEK, Diamyd Medical -1.27 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 86.7%–94.4%.
What to watch next, and why
The earnings report shows how Intervacc's revenue and profit have changed.
- Earnings report
The earnings report shows how Intervacc's revenue and profit have changed.
Add to calendar
More about Intervacc
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Astrid Larberg, senior executiveBuyabout 7 thousand SEK
- Astrid Larberg, senior executiveBuyabout 21 thousand SEK
- Anna Carin Margaretha Lagerlöf, senior executiveBuyabout 10 thousand SEK
- Astrid Larberg, senior executiveBuyabout 4 thousand SEK
- Astrid Larberg, senior executiveBuyabout 12 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Intervacc usually moved about 7.4%. On a normal day it moves 2.0%.
−1.08% −14.82% −16.47% −1.06%
10,000 SEK in Intervacc bought on April 7, 2017 is worth 1,210 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 27,200 SEK.
What would 10,000 SEK in Intervacc be worth today? →
What would 10,000 SEK in Intervacc be worth today?
1,210 SEK
with dividends reinvested, bought on April 7, 2017. The same amount in OMX Stockholm 30 with dividends would have become 27,200 SEK.
At worst it was worth 943 SEK (February 27, 2026).
The five biggest days of the journey
· +76.1% · the whole market rose 0.9% the same day
· +58.3% · the whole market fell 0.2% the same day
· −49.2% · the whole market fell 2.2% the same day
· −40.0% · the whole market fell 0.4% the same day
· +33.0% · the whole market was unchanged the same day
Earlier days
+0.78% market −0.11% Intervacc was roughly flat over the week, while the OMX Stockholm 30 was also roughly flat, so the stock moved against a calm market. Read →
Intervacc was roughly flat over the week, while the OMX Stockholm 30 was also roughly flat, so the stock moved against a calm market.
On Tuesday, the company said real-world data showed only three confirmed strangles cases among horses that finished the primary vaccination with its Strangvac vaccine.
Analysts at DNB Carnegie and Redeye then highlighted the encouraging data, and trading volume was about twice normal.
The stock fell sharply in the last session, while the market fell clearly, so the drop was steeper than the index.
−4.53% market −0.32% Intervacc fell, moving well apart from a market that slipped only slightly. Read →
Intervacc fell, moving well apart from a market that slipped only slightly.
No company news from that session explains the drop with certainty.
Over the last five trading days the shares rose clearly, while the market rose slightly.
−1.71% market +0.83% Intervacc fell slightly, moving against a rising market. Read →
Intervacc fell slightly, moving against a rising market.
The session's move was ordinary for the stock, and no company news from that session explains it.
Over the last five trading days, Intervacc rose sharply, clearly more than OMX Stockholm 30, which rose slightly.
Earlier news, dated the day before the session, was a company update showing strong real-world results for its horse vaccine Strangvac.
Trading volume was well above its usual level, which suggests heavy activity.
+14.38% market −0.08% Intervacc rose sharply on real-world Strangvac data. Read →
Intervacc rose sharply on real-world Strangvac data.
Intervacc rose very sharply in the last session, while the market was roughly flat.
Trading was far heavier than usual.
The move followed company news from that day: real-world data showed only 3 confirmed strangles cases among horses that completed primary vaccination with Strangvac.
Over the last five trading days the shares rose sharply, well ahead of a slight market gain.
−1.03% market −0.29% Intervacc fell slightly without a company-news explanation. Read →
Intervacc fell slightly without a company-news explanation.
In the last five trading days, Intervacc fell sharply while OMX Stockholm 30 rose clearly.
That fall was a big move for Intervacc, roughly twice a normal five-day stretch.
Last session, the stock moved more than the market, but the move was an ordinary size for Intervacc.
Broader Healthcare stocks on Nasdaq First North Sweden also fell over the same days.
−8.85% market +3.01% Intervacc fell sharply over the week while the OMX Stockholm 30 index rose clearly, so the stock moved strongly against the market. Read →
Intervacc fell sharply over the week while the OMX Stockholm 30 index rose clearly, so the stock moved strongly against the market.
Intervacc has had no company news in the past two weeks, so no specific event explains the drop.
The sector gave ground too: the median healthcare stock on Nasdaq First North Sweden slipped over the same days, which points to weaker sentiment in the group.
Its last session was ordinary, with a slight decline in line with the wider market.
−4.68% market +0.96% Intervacc fell sharply, while the market rose clearly. Read →
Intervacc fell sharply, while the market rose clearly.
No company news explains the move.
Over the last five trading days, the shares fell clearly while the market was roughly flat.
The move was big for Intervacc, with trading well above its usual level.
The shares sit well below their high of the past year and well above the low.
−3.42% market +1.57% Intervacc fell clearly, moving against a rising market. Read →
Intervacc fell clearly, moving against a rising market.
No company news explains it.
Over the last five trading days the stock fell clearly, while OMX Stockholm 30 fell slightly.
The stock's price is still well above its lowest close of the past year.
Trading was well below its usual level.
+1.93% market +0.41% Intervacc rose slightly without company news. Read →
Intervacc rose slightly without company news.
The stock moved more than the market, which was also up slightly.
Over the last five trading days it moved against a sharply falling OMX Stockholm 30, rising slightly.
The move was an ordinary one for Intervacc, and trading was quiet.
Next, the earnings report on 12 November may bring new information.
+3.17% market −3.67% Intervacc rose slightly over the last five trading days, moving against a clearly weaker OMX Stockholm 30 market. Read →
Intervacc rose slightly over the last five trading days, moving against a clearly weaker OMX Stockholm 30 market.
Intervacc has had no company news in this period, so there is no specific event behind the move.
Sector and market moves are the likely drivers, with trading in the shares running quieter than usual.
The next earnings report, the company's quarterly results, is due on Thursday 12 November 2026.
−1.19% market −2.51% Intervacc moved little without company news. Read →
Intervacc moved little without company news.
Intervacc fell slightly in the last session, an ordinary day for the stock.
Over the last five trading days it held nearly steady, while OMX Stockholm 30 fell clearly.
No company news explains the move.
Over the same session, the market fell sharply, so Intervacc held up better.
−2.76% market −0.89% Intervacc fell clearly, with no company news to explain it. Read →
Intervacc fell clearly, with no company news to explain it.
Over the last five trading days it fell slightly, while OMX Stockholm 30 also fell slightly, so the stock moved more than the market.
Trading was thin, meaning few shares changed hands, so price moves can be larger.
The next report, its quarterly results, is due on Thursday 12 November.
+5.85% market −0.89% {'text': "Intervacc rose sharply, against a falling market, with no company news explaining it. Read →
{'text': "Intervacc rose sharply, against a falling market, with no company news explaining it.
Over the last five trading days, Intervacc fell slightly while the market was roughly flat.
Trading was about twice a normal day, which suggests heavier interest than usual.
The move was not explained by any company announcement.
Intervacc's next earnings report, its quarterly results, is due on 12 November.", 'events':}
Learn more · Why do stocks move on earnings day? · Why do stocks go up and down?